WALTHAM, Mass.—PerkinElmer Inc. has acquired VisEn Medical Inc., an in vivo molecular imaging technology company based in Bedford, Mass. Financial terms of the deal were not disclosed.
PerkinElmer notes that the acquisition enables it to enhance its cellular imaging business, by expanding the company's technologies and capabilities downstream into preclinical research carried out at academic institutes and pharmaceutical companies.
"We are very pleased to bring VisEn into the PerkinElmer organization," said Richard Eglen, president, Bio-discovery, PerkinElmer. "VisEn provides a compelling offering in molecular imaging platforms and tools that are synergistic with PerkinElmer's existing business. This acquisition broadens our product portfolio along the drug discovery pipeline, from basic disease-based research to preclinical drug discovery applications, through the addition of proprietary chemistries in the emerging and fast growing space of translational biomarker reagents."
VisEn's proprietary fluorescence molecular imaging systems and reagents are currently used in applications involving research in such areas as cancer, inflammation, cardiovascular, skeletal diseases and pulmonary diseases.
"This acquisition will advance further PerkinElmer's mission to assist life sciences and pharmaceutical research in finding additional ways to develop new generations of safer and more effective drugs, as well as better diagnostic capabilities," Eglen says.
The VisEn offering includes its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT) Imaging Systems. These technologies provide quantitative molecular imaging data that can be useful for identifying and characterizing a range of disease biomarkers and therapeutic efficacy in cells and animal models. This cellular imaging approach, combined with PerkinElmer technologies, can enable better screening and optimization of potential new drugs, through translational biomarker research. This can provide an increased correlation of isolated cellular activity with in vivo biological activity, which will allow researchers to get closer to understanding human responses and thereby develop better potential therapies.
VisEn will become part of the Bio-discovery business entity within PerkinElmer, a unit that focuses on the global life science market by offering a broad portfolio of chemistries, detection solutions, imaging solutions and services to researchers and drug discovery scientists worldwide.
PerkinElmer notes that the acquisition enables it to enhance its cellular imaging business, by expanding the company's technologies and capabilities downstream into preclinical research carried out at academic institutes and pharmaceutical companies.
"We are very pleased to bring VisEn into the PerkinElmer organization," said Richard Eglen, president, Bio-discovery, PerkinElmer. "VisEn provides a compelling offering in molecular imaging platforms and tools that are synergistic with PerkinElmer's existing business. This acquisition broadens our product portfolio along the drug discovery pipeline, from basic disease-based research to preclinical drug discovery applications, through the addition of proprietary chemistries in the emerging and fast growing space of translational biomarker reagents."
VisEn's proprietary fluorescence molecular imaging systems and reagents are currently used in applications involving research in such areas as cancer, inflammation, cardiovascular, skeletal diseases and pulmonary diseases.
"This acquisition will advance further PerkinElmer's mission to assist life sciences and pharmaceutical research in finding additional ways to develop new generations of safer and more effective drugs, as well as better diagnostic capabilities," Eglen says.
The VisEn offering includes its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMT) Imaging Systems. These technologies provide quantitative molecular imaging data that can be useful for identifying and characterizing a range of disease biomarkers and therapeutic efficacy in cells and animal models. This cellular imaging approach, combined with PerkinElmer technologies, can enable better screening and optimization of potential new drugs, through translational biomarker research. This can provide an increased correlation of isolated cellular activity with in vivo biological activity, which will allow researchers to get closer to understanding human responses and thereby develop better potential therapies.
VisEn will become part of the Bio-discovery business entity within PerkinElmer, a unit that focuses on the global life science market by offering a broad portfolio of chemistries, detection solutions, imaging solutions and services to researchers and drug discovery scientists worldwide.
The VisEn name will officially become PerkinElmer. Company officials note that the name "VisEn" will be phased out over the coming months, though individual product names will remain the same.
VisEn's portfolio is said to particularly well complement PerkinElmer's focus on cancer, inflammation, epigenetics, and biomarkers as well as PerkinElmer's existing confocal, high-content screening and software imaging solutions.
Founded in 2000 by Ralph Weissleder and Kirtland Poss, VisEn's customer base includes academic imaging facilities and departments, biologists, radiologists, medical imaging facilities (combined with CT/MRI/Ultrasound), pharmaceutical therapeutic research departments, and contract research organizations (CROs). Additionally, VisEn collaborates with pharmaceutical companies to design custom molecular imaging reagents and applications for specific preclinical and clinical research areas.
VisEn's portfolio is said to particularly well complement PerkinElmer's focus on cancer, inflammation, epigenetics, and biomarkers as well as PerkinElmer's existing confocal, high-content screening and software imaging solutions.
Founded in 2000 by Ralph Weissleder and Kirtland Poss, VisEn's customer base includes academic imaging facilities and departments, biologists, radiologists, medical imaging facilities (combined with CT/MRI/Ultrasound), pharmaceutical therapeutic research departments, and contract research organizations (CROs). Additionally, VisEn collaborates with pharmaceutical companies to design custom molecular imaging reagents and applications for specific preclinical and clinical research areas.
